This is clinically relevant because, in hematological malignancies, p53 mutation frequency increases with tumor progression to more aggressive or advanced stages and it is strongly associated with chemo-resistance and poor prognosis [26–29, 55]. This evidence concerns the gene TP53 and neoplasm.